Multiple myeloma affects the mouth and jaw more directly than most people realize, making dental care not just a nice-to-have but a genuine medical priority throughout diagnosis, treatment, and survivorship. Roughly a third of patients with symptomatic myeloma develop lytic bone lesions in the jaws, and the bone-protecting drugs used to manage the disease carry their own serious oral risk: medication-related osteonecrosis of the jaw (MRONJ). The overlap between myeloma treatment and oral health means your dentist and your oncologist need to be in close communication, ideally starting before treatment begins.
How Myeloma Shows Up in the Mouth
Myeloma is a cancer of plasma cells in the bone marrow, and one of its hallmarks is the destruction of bone. Up to 80% of patients have osteolytic bone lesions at diagnosis, and about 60% will develop a fracture during the course of the disease.1Nature. Pathogenesis of bone disease in multiple myeloma: from bench to bedside While the spine and pelvis are the most common sites, the jawbones are far from immune. A systematic review found that about 35% of patients with symptomatic myeloma present with lytic lesions in the jaws.2Oral Oncology Reports. Oral manifestations of multiple myeloma – A systematic review These lesions can appear as “punched-out” dark spots on dental X-rays and sometimes cause swelling, loosening of teeth, or jaw pain that might initially be mistaken for a dental abscess or periodontal disease.
In some cases, the mouth is where myeloma first announces itself. Case reports describe patients whose initial complaint was jaw swelling, and it was the imaging and biopsy work-up that uncovered the underlying myeloma diagnosis.3PubMed Central. Multiple Myeloma with Primary Manifestation in the Mandible Rarer oral signs include macroglossia, a progressive enlargement of the tongue caused by amyloid deposits, which can occur when myeloma is accompanied by AL amyloidosis.4PubMed Central. Progressive Macroglossia and Dysphagia as the Initial Manifestation of Systemic Amyloid Light-Chain (AL) Amyloidosis Associated With Multiple Myeloma This is uncommon, but it underscores why unexplained oral symptoms in someone with known or suspected myeloma should not be dismissed as routine dental problems.
Bisphosphonates, Denosumab, and Why They Complicate Dental Work
One of the cornerstones of myeloma management is bone-modifying therapy. Bisphosphonates like zoledronate and pamidronate, along with denosumab, help reduce bone pain and lower the risk of pathologic fractures. They do not rebuild bone that has already been damaged, but they slow further destruction.5PubMed Central. Multiple Myeloma and the Role of Bisphosphonates in Its Management For most patients, the benefit is substantial. The catch is that these same drugs create a well-documented risk for MRONJ, a condition in which jaw bone exposed to the oral environment fails to heal and slowly dies.
Myeloma is the cancer most frequently associated with MRONJ in the dental and medical literature, accounting for roughly 45% of published osteonecrosis cases. The risk is highest with long-term intravenous bisphosphonates, particularly in older patients. The mandible (lower jaw) is affected more often than the upper jaw, and previous dental procedures are a common trigger.6PubMed Central. Osteonecrosis of the myeloma patients treated with bisphosphonates A study specifically tracking myeloma patients found that the factors most strongly predicting MRONJ were dental extractions, treatment with pamidronate or zoledronate, longer time on therapy, and older age at myeloma diagnosis.7PubMed. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors
Dental infection at the time of extraction appears to make things worse. A retrospective study of 240 patients receiving antiresorptive agents found that having an infection as the reason for extraction significantly raised the odds of MRONJ compared to extractions done for non-infectious reasons.8PubMed. Risk of medication-related osteonecrosis of the jaw after dental extractions in patients receiving antiresorptive agents – A retrospective study of 240 patients The practical takeaway is twofold: preventing infections from developing in the first place lowers risk, and when an extraction is unavoidable, the timing relative to your last bisphosphonate dose matters.
The Pre-Treatment Dental Visit
The single most impactful thing you can do for your oral health as a myeloma patient is to see a dentist before bone-modifying therapy starts. Major clinical practice guidelines, including those from the Multinational Association of Supportive Care in Cancer (MASCC), recommend a full clinical and radiographic dental assessment before antiresorptive therapy begins, followed by dental check-ups every three to six months once it is underway.9British Dental Journal. Medication-related osteonecrosis of the jaw in multiple myeloma patients: a case series The goal is to resolve any ticking time bombs in advance: treat active periodontal disease, fill cavities, adjust dentures that are rubbing against the gums, and extract any teeth that are clearly failing. All of this is far safer to do before the bisphosphonate or denosumab enters the picture.
If you are already on antiresorptive therapy and an invasive procedure like an extraction becomes necessary, oncologists and oral surgeons may discuss a “drug holiday,” pausing the bisphosphonate for a period before the procedure. The standard suggestion has been a two- to three-month withdrawal, though evidence for its effectiveness remains limited.10Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology. Duration of drug holiday of oral bisphosphonate and osteoclast morphology in osteoporosis patients with medication-related osteonecrosis of the jaw A large 2025 study in osteoporotic patients receiving intravenous bisphosphonates found that pausing treatment for more than 90 days was associated with substantially lower MRONJ risk, and the risk was lowest when the pause exceeded a year. The benefit appeared more consistent with ibandronate than with zoledronate, where only pauses longer than a year showed a clear association.11PubMed Central. Time since last intravenous bisphosphonate and risk of osteonecrosis of the jaw in osteoporotic patients These findings are from osteoporosis patients rather than myeloma patients specifically, so the exact drug-holiday timing for myeloma should be worked out between your oncologist and your dentist or oral surgeon, weighing the bone-fracture risk of stopping the drug against the jaw risk of continuing it.
Oral Side Effects During Active Myeloma Treatment
Beyond the bone medications, the chemotherapy and transplant protocols used for myeloma can take a toll on the soft tissues of the mouth. High-dose melphalan, a cornerstone of the conditioning regimen before autologous stem cell transplant, is a common culprit for oral mucositis, painful inflammation and ulceration of the mouth lining. Some transplant centers use cryotherapy, having patients suck on ice chips starting before the melphalan infusion and continuing for a couple of hours afterward, to constrict the blood vessels in the mouth and limit the drug’s contact with the oral tissues.12PubMed Central. The incidence of severe oral mucositis in patients undergoing different conditioning regimens in haematopoietic stem cell transplantation Saline and sodium bicarbonate mouthwashes are also standard preventive measures during transplant hospitalization.
During the period when white blood cell counts are at their lowest after transplant, even gentle tooth brushing can become a source of infection. Some protocols switch patients from a regular toothbrush to soft foam swabs and have them rinse with chlorhexidine solution after every meal to keep bacterial load down without traumatizing the inflamed gums.13Scientific Reports. Female sex as an independent prognostic factor in the development of oral mucositis during autologous peripheral stem cell transplantation These transplant centers also do a dental check-up before the procedure to identify and remove any infection sources in advance, echoing the same preventive logic used before starting bisphosphonates.
Other myeloma therapies, including proteasome inhibitors and immunomodulatory drugs, have their own potential for oral and maxillofacial side effects, though MRONJ from antiresorptive agents remains the best-documented concern.14PubMed Central. Review of Myeloma Therapies and Their Potential for Oral and Maxillofacial Side Effects Dry mouth, altered taste, and increased susceptibility to oral infections can all show up at various points during treatment, though the severity varies from person to person.
What Happens If MRONJ Develops
Despite best efforts, some patients do develop MRONJ. The classic presentation is exposed bone in the mouth that does not heal over eight weeks, often accompanied by pain, swelling, and sometimes infection of the surrounding tissue. Early-stage MRONJ may be managed conservatively with antibiotics to control secondary infection, antiseptic mouth rinses, and careful monitoring. Clinical guidelines predominantly recommend antibiotic therapy as the first-line non-surgical approach, since it addresses the infection that often accompanies the necrotic bone.15PubMed. Medication-related osteonecrosis of the jaw: evolving research for multimodality medical management
When conservative management is not enough, more advanced approaches are emerging. Treatments including teriparatide (a bone-building hormone), photobiomodulation therapy (low-level laser therapy), and pentoxifylline combined with vitamin E have shown promise in promoting healing and potentially avoiding surgery. These are still being validated in larger studies, but the trend in MRONJ management is toward exploring multiple medical options before resorting to surgical removal of dead bone. For myeloma patients specifically, any decision about teriparatide or similar agents has to be made carefully with the oncology team, since drugs that stimulate bone turnover could have implications for the underlying cancer.
Everyday Dental Hygiene with Myeloma
One somewhat reassuring finding is that myeloma patients do not necessarily have worse teeth than the general population in terms of cavities and decay. A study comparing the dental status of myeloma patients with matched controls found that while both groups had high levels of tooth decay, fillings, and missing teeth, the overall scores were not significantly different between the two groups.16PubMed Central. Oral health status of patients with multiple myeloma Myeloma patients did have fewer filled teeth, which may reflect less access to or less engagement with routine dental care after diagnosis rather than a difference in underlying oral health. About 70% of the myeloma patients in the study needed some form of prosthetic rehabilitation, like crowns or partial dentures.
The practical advice for daily oral care is not exotic, but it becomes more consequential when the stakes include MRONJ. Brush gently twice a day with a soft-bristled brush, floss daily, and keep up with professional cleanings on the schedule your dental team recommends. Prevention of periodontal disease and cavities is not just about keeping your teeth attractive; it directly reduces the likelihood that you will need extractions or other invasive procedures down the line. Since extractions are the single biggest trigger for MRONJ in patients on antiresorptive drugs, every cavity you prevent and every infection you catch early is an investment in avoiding that complication. Work with your dental team to address any ill-fitting dentures quickly, since chronic mucosal irritation is another recognized risk factor.
How Oral Problems Affect Quality of Life
The mouth matters for more than just eating. A longitudinal cohort study of myeloma patients found that about 30% reported oral pain or discomfort related to their medical treatment.17PubMed Central. Oral health, dental treatment, and medication related osteonecrosis of the jaw in multiple myeloma – a longitudinal cohort study Research on patients with blood cancers has shown that poor oral health significantly compromises quality of life across multiple dimensions, including physical pain, psychological discomfort, and social functioning.18Hematology, Transfusion and Cell Therapy. THE IMPACT OF ORAL HEALTH ON QUALITY OF LIFE IN PATIENTS WITH ONCO-HEMATOLOGICAL DISEASES People with mouth pain eat less, speak less, and withdraw socially. When you are already dealing with the fatigue, bone pain, and emotional weight of a myeloma diagnosis, oral problems can feel like one burden too many.
This is one reason why the pre-treatment dental assessment is so important. It is far easier to prevent oral complications than to treat them in a patient who is immunocompromised, on antiresorptive therapy, and dealing with the psychological toll of cancer treatment. Addressing dental issues proactively is as much about preserving quality of life as it is about avoiding MRONJ.
The Financial Reality of Dental Care During Myeloma
Myeloma treatment is expensive, and dental care often falls through the cracks of insurance coverage. In the United States, many health insurance plans cover medical treatment but offer limited or no dental benefits, which creates a real gap for cancer patients whose dental needs suddenly become medically urgent. A study of patients with myeloma and chronic lymphocytic leukemia treated at U.S. community oncology clinics found that a meaningful proportion of patients reported being unable to afford dental care within the past year, with dental care being one of the specific needs patients had to forgo due to cost.19PubMed Central. Self-Reported Financial Difficulties Among Patients with Multiple Myeloma and Chronic Lymphocytic Leukemia Treated at U.S. Community Oncology Clinics (Alliance A231602CD)
If you are facing this kind of squeeze, it is worth asking your oncology social worker about resources. Some cancer centers have partnerships with dental schools that provide reduced-cost care. Organizations like the Leukemia & Lymphoma Society sometimes offer financial assistance that can cover ancillary medical needs. The key thing is not to let cost silently push dental care off your priority list, since skipping cleanings or ignoring a growing cavity can set you up for exactly the kind of emergency extraction that carries the highest MRONJ risk.
Communicating Between Your Dental and Oncology Teams
One of the most common practical failures in myeloma dental care is not clinical but logistical: your dentist does not know what drugs you are on, or your oncologist does not know you need an extraction next month. If your dental office and your cancer center are not part of the same health system, information may not flow automatically. You can bridge that gap by keeping a brief written summary of your current myeloma medications, including bisphosphonate or denosumab name, dose schedule, and date of last infusion, and handing it to your dental team at every visit. Likewise, let your oncologist know about any upcoming dental work so the team can plan drug holidays or antibiotic prophylaxis if needed.
Your dentist should know not just whether you are on a bisphosphonate, but which one and for how long. The cumulative duration of bisphosphonate exposure is one of the variables that predicts MRONJ risk.7PubMed. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors A patient who has been on monthly zoledronate for four years is in a different risk category than someone who started three months ago. Without that information, your dentist is flying blind when deciding whether a routine extraction can proceed or whether a more cautious approach is warranted.
Saliva as a Monitoring Tool
An interesting area of emerging research involves using saliva to monitor myeloma disease burden. Researchers have identified a protein called FABP5 that increases in saliva as myeloma progresses from a precursor condition to full-blown symptomatic disease, and decreases after treatment, suggesting it tracks with tumor burden.20PubMed. Saliva-omics in plasma cell disorders- Proof of concept and potential as a non-invasive tool for monitoring disease burden The appeal is obvious: saliva collection is painless and can be done at home, unlike the blood draws and bone marrow biopsies that myeloma patients currently endure for monitoring.
Before anyone gets too excited, though, there are real limits. A separate study looked at whether the abnormal antibodies (M-proteins) that define myeloma could be reliably detected in saliva, and concluded that saliva is not clinically useful for detecting or monitoring M-protein or free light chain production in myeloma.21PubMed Central. Investigating the utility of saliva immunoglobulins for the detection of myeloma and using myeloma proteins to clarify partition between oral and systemic immunity So while salivary biomarkers like FABP5 show proof-of-concept promise as research tools, saliva is not replacing blood tests for myeloma monitoring any time soon. It remains a space to watch rather than a tool to rely on.